Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)

By Maindrault-Goebel F.   Louvet C.   Andre T.   Carola E.   Lotz J.P.   Molitor J.L.   Garcia M.L.   Gilles-Amar V.   Izrael V.   Krulik M.   de Gramont A.  

European Journal of Cancer, Vol. 35, Iss. 9, 1999-09 ,pp. : 1338-1342

Elsevier

Access to resources Recommend Favorite

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

By Pfeiffer Per   Nielsen Dorte   Yilmaz Mette   Iversen Anja   Vejlø Christian   Jensen Benny Vittrup  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 697-701

Informa Healthcare

Access to resources Recommend Favorite

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)

By Maindrault-Goebel F.   de Gramont A.   Louvet C.   Andre T.   Carola E.   Mabro M.   Artru P.   Gilles V.   Lotz J.P.   Izrael V.   Krulik M.   for the Oncology Multidisciplinary Research Group GERCOR  

European Journal of Cancer, Vol. 37, Iss. 8, 2001-05 ,pp. : 1000-1005

Elsevier

Access to resources Recommend Favorite

Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU - a retrospective comparison of treatment regimens

By Iveson T.J.   Hickish T.   Schmitt C.   Van Cutsem E.  

European Journal of Cancer, Vol. 35, Iss. 13, 1999-12 ,pp. : 1796-1804

Elsevier

Access to resources Recommend Favorite

Adjuvant Therapy with Raltitrexed in Patients with Colorectal Cancer Intolerant of 5-Fluorouracil: British Columbia Cancer Agency Experience

By Wilson Kenneth   Fitzgerald Catherine   Barnett Jeff   Pharm B.   Gill Sharlene   Khoo Kong  

Cancer Investigation, Vol. 25, Iss. 8, 2007-11 ,pp. : 711-714

Informa Healthcare

Access to resources Recommend Favorite